RSS | Login | Register

SPECTRACEF

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare SPECTRACEF to:

Generic Name for SPECTRACEF

Cefditoren (as pivoxil) 200mg; tabs.

Legal Classification:

Pharmacological Class for SPECTRACEF

Cephalosporin.

Manufacturer of SPECTRACEF

Cornerstone Therapeutics, Inc.

Indications for SPECTRACEF

Susceptible mild to moderate acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, uncomplicated skin and skin structure infections.

Adult dose for SPECTRACEF

Take with meals. Bronchitis: 400mg twice daily for 10 days. Pneumonia: 400mg twice daily for 14 days. Pharyngitis/tonsillitis, skin and skin structure: 200mg twice daily for 10 days. Renal impairment (CrCl 30–49mL/min): max 200mg twice daily; CrCl <30mL/min: max 200mg once daily; ESRD: contact manufacturer.

Children's dosing for SPECTRACEF

Not recommended.

Contraindications for SPECTRACEF

Milk protein allergy (not lactose intolerance). Carnitine deficiency or conditions causing carnitine deficiency.

Warnings/Precautions for SPECTRACEF

Penicillin or other allergy. Not for long-term therapy. Decreased muscle mass (risk of carnitine deficiency). Monitor prothrombin time in renal or hepatic impairment or poor nutritional state. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.

Interactions for SPECTRACEF

Avoid drugs that reduce gastric acidity. Potentiated by probenecid. May cause false (+) glucose test with Clinitest, Fehling's or Benedict's soln, Coomb's test; false (–) with ferricyanide test.

Adverse Reactions for SPECTRACEF

GI upset, headache, transient reduction in plasma carnitine levels.

How is SPECTRACEF supplied?

Tabs—60

Related Disease:

Bronchitis, chronic

Infections, bacterial~systemic antiinfectives

Pneumonia

Tygacil labeling updated to include increased mortality risk

September 01, 2010

The FDA is reminding healthcare professionals that intravenous Tygacil (tigecycline, from Pfizer) can increase mortality risk in the treatment of serious bacterial infections.

Phase 3 study of torezolid for acute bacterial skin and skin structure infections

August 30, 2010

Trius Therapeutics announced the initiation of its Phase 3 study of oral torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

FDA warns of eosinophilic pneumonia risk with Cubicin

July 29, 2010

The FDA has notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia while receiving the antibiotic Cubicin (daptomycin, from Cubist).

FDA warns of counterfeit Tamiflu product

June 18, 2010

The FDA has warned consumers about a potentially harmful product represented as "Generic Tamiflu" sold over the Internet.

Claris Lifesciences' intravenous medications recalled

June 01, 2010

The FDA has notified healthcare professionals not to use the intravenous medications, metronidazole, ciprofloxacin and ondansetron manufactured by Claris Lifesciences due to contamination.